-
Something wrong with this record ?
Practical guide for identifying unmet clinical needs for biomarkers
PJ. Monaghan, S. Robinson, D. Rajdl, PMM. Bossuyt, S. Sandberg, A. St John, M. O'Kane, L. Lennartz, R. Röddiger, SJ. Lord, CM. Cobbaert, AR. Horvath,
Language English Country Italy
Document type Journal Article
NLK
PubMed Central
from 1999
Europe PubMed Central
from 1999
Open Access Digital Library
from 2008-01-01
PubMed
30050396
Knihovny.cz E-resources
- Publication type
- Journal Article MeSH
The development and evaluation of novel biomarkers and testing strategies requires a close examination of existing clinical pathways, including mapping of current pathways and identifying areas of unmet need. This approach enables early recognition of analytical and clinical performance criteria to guide evaluation studies, in a cyclical and iterative manner, all the time keeping the clinical pathway and patient health outcomes as the key drivers in the process. The Test Evaluation Working Group of the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM TE-WG) https://www.eflm.eu/site/page/a/1158 has published a conceptual framework of the test evaluation cycle which is driven by the clinical pathway, inherent to which is the test purpose and role within the pathway that are defined by clinical need. To supplement this framework, the EFLM TE-WG has also published an interactive checklist for identifying unmet clinical needs for new biomarkers; a practical tool that laboratories, clinicians, researchers and industry can equally use in a consistent manner when new tests are developed and before they are released to the market. It is hoped that these practical tools will provide consistent and appropriate terminology in this diverse field and offer a platform that facilitates greater consultation and collaboration between all stakeholders. The checklist should assist the work of all colleagues involved in the discovery of novel biomarkers and implementation of new medical tests. The tool is aligned with the IOM recommendations and the FDA and CE regulating body's requirements.
Abbott Diagnostics Wiesbaden Germany
ARC Consulting Perth Australia
Medical and Scientific Affairs CPS Roche Diagnostics GmbH Mannheim Germany
The Christie Pathology Partnership The Christie NHS Foundation Trust Manchester United Kingdom
Thermo Fisher Scientific Clinical Mass Spectrometry Clinical Diagnostics Systems United Kingdom
- 000
- 00000naa a2200000 a 4500
- 001
- bmc18034348
- 003
- CZ-PrNML
- 005
- 20181114141755.0
- 007
- ta
- 008
- 181008s2018 it f 000 0|eng||
- 009
- AR
- 035 __
- $a (PubMed)30050396
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a it
- 100 1_
- $a Monaghan, Phillip J $u The Christie Pathology Partnership, The Christie NHS Foundation Trust, Manchester, United Kingdom.
- 245 10
- $a Practical guide for identifying unmet clinical needs for biomarkers / $c PJ. Monaghan, S. Robinson, D. Rajdl, PMM. Bossuyt, S. Sandberg, A. St John, M. O'Kane, L. Lennartz, R. Röddiger, SJ. Lord, CM. Cobbaert, AR. Horvath,
- 520 9_
- $a The development and evaluation of novel biomarkers and testing strategies requires a close examination of existing clinical pathways, including mapping of current pathways and identifying areas of unmet need. This approach enables early recognition of analytical and clinical performance criteria to guide evaluation studies, in a cyclical and iterative manner, all the time keeping the clinical pathway and patient health outcomes as the key drivers in the process. The Test Evaluation Working Group of the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM TE-WG) https://www.eflm.eu/site/page/a/1158 has published a conceptual framework of the test evaluation cycle which is driven by the clinical pathway, inherent to which is the test purpose and role within the pathway that are defined by clinical need. To supplement this framework, the EFLM TE-WG has also published an interactive checklist for identifying unmet clinical needs for new biomarkers; a practical tool that laboratories, clinicians, researchers and industry can equally use in a consistent manner when new tests are developed and before they are released to the market. It is hoped that these practical tools will provide consistent and appropriate terminology in this diverse field and offer a platform that facilitates greater consultation and collaboration between all stakeholders. The checklist should assist the work of all colleagues involved in the discovery of novel biomarkers and implementation of new medical tests. The tool is aligned with the IOM recommendations and the FDA and CE regulating body's requirements.
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Robinson, Sarah $u Thermo Fisher Scientific. Clinical Mass Spectrometry Clinical Diagnostics Systems, United Kingdom.
- 700 1_
- $a Rajdl, Daniel $u Department of Clinical Biochemistry and Hematology, Medical Faculty in Pilsen, Charles University, Czech Republic.
- 700 1_
- $a Bossuyt, Patrick M M $u Department of Clinical Epidemiology, Biostatistics & Bioinformatics, Academic Medical Center, University of Amsterdam, The Netherlands.
- 700 1_
- $a Sandberg, Sverre $u Laboratory of Clinical Biochemistry, Haukeland University Hospital, Helse Bergen HF, Bergen, Norway, Norwegian Quality Improvement of Laboratory examinations (Noklus), Haraldsplass Deaconess Hospital, Bergen, Norway and Department of Global Health and Primary Health Care, University of Bergen, Norway.
- 700 1_
- $a St John, Andrew $u ARC Consulting, Perth, Australia.
- 700 1_
- $a O'Kane, Maurice $u Clinical Chemistry Department, Altnagelvin Hospital, Western Health and Social Care Trust, Londonderry, N. Ireland, United Kingdom.
- 700 1_
- $a Lennartz, Lieselotte $u Abbott Diagnostics, Wiesbaden, Germany.
- 700 1_
- $a Röddiger, Ralf $u Medical and Scientific Affairs, CPS, Roche Diagnostics GmbH, Mannheim, Germany.
- 700 1_
- $a Lord, Sarah J $u School of Medicine, University of Notre Dame, Sydney, Australia. National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Australia.
- 700 1_
- $a Cobbaert, Christa M $u Department of Clinical Chemistry and Laboratory Medicine, Leiden University Medical Centre, The Netherlands. For the Test Evaluation Working Group of the European Federation of Clinical Chemistry and Laboratory Medicine.
- 700 1_
- $a Horvath, Andrea R $u New South Wales Health Pathology, Department of Clinical Chemistry and Endocrinology, Prince of Wales Hospital and School of Medical Sciences, University of New South Wales, Australia. School of Public Health, University of Sydney, Australia. For the Test Evaluation Working Group of the European Federation of Clinical Chemistry and Laboratory Medicine.
- 773 0_
- $w MED00196631 $t EJIFCC $x 1650-3414 $g Roč. 29, č. 2 (2018), s. 129-137
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/30050396 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20181008 $b ABA008
- 991 __
- $a 20181114141842 $b ABA008
- 999 __
- $a ind $b bmc $g 1341160 $s 1031342
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2018 $b 29 $c 2 $d 129-137 $e 20180711 $i 1650-3414 $m EJIFCC $n EJIFCC $x MED00196631
- LZP __
- $a Pubmed-20181008